Table 4 Serum albumin and survival - multiple cancer sites
First author, year of publication, place | Year of data collection | Study design, Sample size | Cancer type | Groups being compared | RR (95%Cl), p-value | Variables adjusted for |
|---|---|---|---|---|---|---|
Penel N, 2008, USA [82] | October 1997 to October 2002 | Retrospective consecutive case series, 148 | Breast, colon, rectum, head and neck, lung, others | >=3.8 g/dL <3.8 g/dL | Univariate: Median overall survival (days) <38 g/l: 91 (1-2421) >=38 g/l: 363 (296-429), p = 0.00001 Multivariate: 2.51 (1.51-4.18); 0.0001 | Primary site, liver metastases, other viscera metastases, BMI, lymphocyte count, granulocyte count |
Lam PT, 2007, Hongkong [12] | January to December 2002 | Prospective cohort, 170 | Lung, liver, lower gastrointestinal tract, breast, gynecological, haematological, nasopharyngeal, prostate, unknown, others | Continuous variable | Univariate: 0.94 (0.91-0.96), <0.001 Multivariate: 0.95 (0.92-0.98), 0.001 | Demographic data, tumor characteristics, blood parameters, functional status, comorbidities, total symptom score, and psychosocial parameters |
Santarpia L, 2006, Italy [83] | January 1996 to September 2003 | Retrospective, 152 | Stomach, ovaries, colorectal, endometrium, breast, ileum, gallbladder, pancreas, kidney, skin, prostate, abdominal sarcoma, unknown | Mean (SD) 2.8 +/-0.6 g/dL 3.1+/- 0.5 g/dL 3.3+/- 0.6 g/dL | Survival in days For 2.8 +/-0.6 g/dL = <30 days For 3.1+/- 0.5 g/dL = 30-90 days For 3.3+/- 0.6 g/dL = >90 days p = 0.001 | Age, gender, height, weight, BMI, hemoglobin, lymphocyte count, cholesterol, CHE, KPS score, pain, ascites, vomiting |
Pasanisi F, 2001, Italy [84] | 1995-1999 | Retrospective consecutive case series, 76 | Stomach, colorectal, ovary, others | Mean (SD) 3.13 +/- .51 g/dL 3.57 +/- .43 g/dL | Survival in months For 3.13 +/- .51 g/dL <= 3 months For 3.57 +/- .43 g/dL > 3 months P = 0.002 | Age, weight, BMI, hemoglobin, lymphocyte count, cholesterol, pain and ascites |
Vigano A, 2000, Canada [85] | July 1, 1996, to December 31, 1998 | A prospective cohort of 227 consecutive patients | Breast, gastrointestinal, lung | >=3.5 g/dL <3.5 g/dL | Univariate: 1.9 (1.4-2.8), <0.01 Multivariate: 7.3 (2.9-18.1) | Lung primary tumor, presence of liver metastases, tumor burden, co morbidity, performance status, weight loss, lymphocyte count, nausea, LDH |
Maltoni M, 1997, Italy [86] | NA | Prospective consecutive case series, 519 | Solid tumors excluding renal cancer and hematological cancer | Normal: 3.3-5.5 g/dL Low: 2.7-3.2 g/dL Very low: <=2.6 g/dL | Univariate: p = 0.0015 Median length of survival (days): Normal =40.0 low = 29.5 Very low = 24.0 months | Total WBC, neutrophil percentage, lymphocyte percentage, proteinuria, pseudocholinesterase |